Six years ago, we set out to close a fundamental gap in drug discovery: cancer therapies built on targets that aren't unique to the tumor, often at a cost to patients. Kudos to those who set big goals and do the work behind our mission to treat every patient with cancer.

CEO & co-founder Kevin Parker will join several investor conferences this year to share our differentiated pipeline of antibody-based #cancer therapies. More here: businesswire.com/news/home/2…

To be precise: new look, same mission. Find us at cartography.bio/

Excited for #BIO2026. Since last year's conference, CBI-1214 entered the clinic, we've announced new strategic collaborations, and secured financing to advance next-generation tumor-selective cancer therapies. We're looking forward to connecting with investors and partners.

#ASCO26: Sat 5/30, 9 AM–12 PM CDT, Poster 442a. We're presenting the Phase 1, first-in-human study design for CBI-1214, our LY6G6D-targeted T-cell engager, in advanced/metastatic MSS/MSI-L colorectal cancer, a population with deep unmet need.

CEO Kevin Parker takes the stage on Wed, May 27 at #AETEurope to share how single-cell genomics is helping us find the antigen targets and target pairs behind the next generation of T-cell engagers.

We’re pleased to share that we've received a strategic investment from @SamsungVentures to advance our oncology pipeline and proprietary drug discovery platform. Read more: businesswire.com/news/home/2…

Looking ahead to #AACR2026, where we’ll present new preclinical data on CB02, a novel tumor-associated antigen in AML and solid tumors identified using our ATLAS platform.

During #NationalColorectalCancerAwarenessMonth, we recognize the patients & families working to change the trajectory of colorectal cancer. We’re advancing CBI-1214, targeting LY6G6D, in a Phase 1 trial for MSS/MSI-L CRC to help expand treatment options for patients. #EnoughCRC

We’ve dosed the 1st patient in our Phase 1 trial of CBI-1214, targeting LY6G6D in MSS/MSI-L colorectal cancer. This milestone marks our clinic entry with a selectively engineered program advancing more precise options for hard-to-treat cancers. Read more: businesswire.com/news/home/2…

In a recent @BiotechTV conversation with Chloe Kirk, CEO Kevin Parker was asked when Cartography truly felt like it had hit its "aha" moment. His answer reflects a defining inflection point and the momentum that continues to carry us into the year ahead. Listen in below.

#ICYMI CEO Kevin Parker spoke with @ky_lahucik at @Endpts about the Pfizer deal announced earlier this week, including why Cartography’s platform continues to resonate with large pharma. Read more below. endpoints.news/cartography-d…

Wrapping up 2025, we’re grateful for meaningful progress at Cartography, including IND approval for CBI-1214, a step toward delivering more precise, tumor-targeted therapies to patients in need. Thank you to our team & partners for advancing our mission, & Happy New Year!

We've received FDA IND approval & Fast Track designation for CBI-1214, our lead T-cell engager for colorectal #cancer. These milestones support advancement into Phase 1 & address a significant unmet need in CRC. Read more: businesswire.com/news/home/2…

#JPM26 is only one month away! We continue to advance our platform to uncover novel, tumor-selective targets & look forward to sharing more on our lead program, CBI-1214, which is progressing toward the clinic for patients with colorectal #cancer.